CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc . (“XORTX” or Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies for the treatment of progressive kidney disease and gout, announces that the company has changed its auditor from Smythe LLP, Certified Professional Accountants (formerly Auditor) to Davidson & Company LLP, Certified Professional Accountants, (successor auditor) dated January 16, 2025.
The Board of Directors of XORTX accepted the resignation of the former auditor effective January 16, 2025 and appointed a successor auditor as the Company’s new auditor effective January 16, 2025, who will hold office until the close of the next annual meeting of the Company. shareholders.
There were no reservations in the audit reports of the former auditor for any financial period during which the former auditor was the auditor of the Company. There are no “reportable events” (as defined in National Instrument 51-102 – Continuous Disclosure Obligations) between the Company and the former auditor.
Pursuant to National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the former auditor and the successor auditor, have been reviewed by the Company’s audit committee and board of directors and are filed on the Company’s SEDAR+. profile at www.sedarplus.ca.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our flagship, XRx-008 program for ADPKD; 2) our XRx-026 program for the treatment of allopurinol-intolerant gout; and 3) our secondary program in XRx-101 for acute kidney injury and other acute organ injury associated with coronavirus / COVID-19 infection. In addition, XRx-225 is a preclinical program for type 2 diabetic nephropathy. XORTX is working to advance its clinical development products that target abnormal purine metabolism and xanthine oxidase to reduce or inhibit uric acid production. At XORTX, we are dedicated to developing medicines to improve the quality of life and health of kidney disease patients and individuals with gout. Additional information about XORTX is available at www.xortx.com.
| For more information, contact: | |
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com or +1 403 455 7727 | nick@alpineequityadv.com or +1 617 901 0785 |
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved of the content of this press release. No stock exchange, securities commission or other regulatory body has approved or disapproved of the information contained herein.
Source: XORTX Therapeutics Inc.
